Tags : 1L Therapy

Junshi Reports Results of Dual Regimen in P-III Jupiter-02 Study

Shots:   The P-III Jupiter-02 Study involve assessing of Toripalimab vs PBO in combination with + Gemcitabine/ Cisplatin for 1L treatment of 289 patients with recurrent or metastatic NPC The study resulted in meeting its pre-specified 1EPs of PFS and has expanded the PFS. The company will submit the BLA to NMPA & other countries Toripalimab […]Read More

Innovent Report Results of Dual Regimen in P-III ORIENT-32 Study

Shot:     The P-III ORIENT-32 involves assessing of Tyvyt (sintilimab) + Byvasda (bevacizumab, biosimilar) vs sorafenib in a ratio (2:1) for 1L treatment of patients with advanced HCC The study resulted in meeting its 1EPs of PFS and OS, the safety profile is consistent with prior studies, and no new safety signals were identified. Following the […]Read More